MMR vaccine
Sponsors
Sri Edupuganti, MD MPH, MCM Vaccines B.V., The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz), Serum Institute of India Pvt. Ltd., Emory University
Conditions
Bacterial InfectionsCOPDChickenpoxCondylomata AcuminataDiphteria, Tetanus and PertussisHigh Risk for HIVImmune Response to MMR VaccineMMR Vaccine
Phase 1
Phase 3
Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)
CompletedNCT01553279
Start: 2012-03-30End: 2013-09-27Updated: 2019-03-28
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
CompletedNCT03547271
Start: 2018-12-14End: 2023-05-24Updated: 2025-03-03
Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts
NCT03853785
Start: 2020-02-29End: 2021-12-31Target: 45Updated: 2019-03-12
Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis
CompletedNCT04475081
Start: 2020-09-22End: 2022-05-15Updated: 2024-11-26
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
RecruitingNCT06740630
Start: 2025-01-10End: 2027-05-13Target: 1840Updated: 2025-03-07
A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
RecruitingNCT06806137
Start: 2025-05-15End: 2027-05-03Target: 600Updated: 2025-12-04
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
RecruitingNCT06855160
Start: 2025-04-17End: 2027-02-02Target: 900Updated: 2025-12-04
Phase 4
Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
CompletedNCT01777529
Start: 2012-10-31End: 2013-12-31Updated: 2016-07-11
Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children
CompletedNCT02253407
Start: 2014-09-30End: 2016-02-29Updated: 2018-03-14
Live Vaccines and Innate Immune Training in COPD.
CompletedNCT06257212
Start: 2024-02-28End: 2025-08-25Updated: 2026-03-19
Study of Concomitant Administration of the sIPV and DTaP or MMR
Not yet recruitingNCT06920069
Start: 2025-05-15End: 2031-06-15Target: 2640Updated: 2025-04-17